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Background. Thousands of systematic reviews have been conducted in all areas of health care. However, the methodological
quality of these reviews is variable and should routinely be appraised. AMSTAR is a measurement tool to assess systematic
reviews. Methodology. AMSTAR was used to appraise 42 reviews focusing on therapies to treat gastro-esophageal reflux
disease, peptic ulcer disease, and other acid-related diseases. Two assessors applied the AMSTAR to each review. Two other
assessors, plus a clinician and/or methodologist applied a global assessment to each review independently. Conclusions. The
sample of 42 reviews covered a wide range of methodological quality. The overall scores on AMSTAR ranged from 0 to 10 (out
of a maximum of 11) with a mean of 4.6 (95% CI: 3.7 to 5.6) and median 4.0 (range 2.0 to 6.0). The inter-observer agreement of
the individual items ranged from moderate to almost perfect agreement. Nine items scored a kappa of .0.75 (95% CI: 0.55 to
0.96). The reliability of the total AMSTAR score was excellent: kappa 0.84 (95% CI: 0.67 to 1.00) and Pearson’s R 0.96 (95% CI:
0.92 to 0.98). The overall scores for the global assessment ranged from 2 to 7 (out of a maximum score of 7) with a mean of 4.43
(95% CI: 3.6 to 5.3) and median 4.0 (range 2.25 to 5.75). The agreement was lower with a kappa of 0.63 (95% CI: 0.40 to 0.88).
Construct validity was shown by AMSTAR convergence with the results of the global assessment: Pearson’s R 0.72 (95% CI: 0.53
to 0.84). For the AMSTAR total score, the limits of agreement were 20.1961.38. This translates to a minimum detectable
difference between reviews of 0.64 ‘AMSTAR points’. Further validation of AMSTAR is needed to assess its validity, reliability
and perceived utility by appraisers and end users of reviews across a broader range of systematic reviews.
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INTRODUCTION
High quality systematic reviews are increasingly recognized as
providing the best evidence to inform health care practice and
policy [1]. The quality of a review, and so its worth, depends on
the extent to which, scientific review methods were used to
minimize the risk of error and bias. The quality of published
reviews can vary considerably, even when they try to answer the
same question [2]. As a result, it is necessary to appraise their
quality (as is done for any research study) before the results are
implemented into clinical or public health practice. Much has
been written on how best to appraise systematic reviews, and while
there is some variation on how this is achieved, most agree on key
components of the critical appraisal [3]. Methodological quality
can be defined as the extent to which the design of a systematic
review will generate unbiased results [4].
Several instruments exist to assess the methodological quality of
systematic reviews [5], but not all of them have been developed
systematically or empirically validated and have achieved general
acceptance. The authors of this paper acknowledge that the
methodological quality and reporting quality for systematic reviews
is very different. The first, methodological quality, considers how well the
systematic review was conducted (literature searching, pooling of
data, etc.). The second, reporting quality, considers how well systematic
reviewers have reported their methodology and findings. Existing
instruments often try to include both types of methods without being
conceptually clear about the differences.
In an attempt to achieve some consistency in the evaluation of
systematic reviews we have developed a tool to assess their
methodological quality. This builds on previous work [6], and is
based on empirical evidence and expert consensus. A measure-
ment tool to assess systematic reviews (AMSTAR) was highly rated
in a recent review (personal communication) of quality assessment
instruments performed by the Canadian Agency for Drugs and
Technologies in Health (CADTH). In this study we present the
results of an external validation of AMSTAR using data from a
series of systematic reviews obtained from the gastroenterology
literature.
METHODS
The characteristics and basic properties of the instrument have
been described elsewhere [7]. Briefly, a 37-item initial assessment
tool was formed by combining a) the enhanced Overview Quality
Assessment Questionnaire (OQAQ) scale, b) a checklist created by
Sacks, and c) three additional items recently judged by experts in
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the field to be of methodological importance. In its development
phase the instrument was applied to 99 paper-based and 52
electronic systematic reviews [6] [7]. Exploratory factor analysis
was used to identify underlying components. The results were
considered by methodological experts using a nominal group
process to reduce the number of items and design an assessment
tool with face and content validity. This process lead to an 11-item
instrument [7]. A description of the instrument is provided in
Annex S1.
External validity
For our validation test set we chose to use systematic reviews or
meta-analyses in the area of gastroenterology, specifically upper
gastrointestinal. CADTH’s informational specialist searched
electronic bibliographic databases (i.e. Medline, Central and
EMBASE) up to and including 2005. A total of 42 systematic
reviews met the a priori criteria and were included [8]. This sample
included seven electronic Cochrane systematic reviews and 35
paper-based non-Cochrane reviews. The topics of the reviews
ranged across the spectrum of GI problems like dyspepsia, gastro-
esophageal reflux disease (GERD), peptic ulcer disease (PUD), and
also GI drug interventions such as H2 receptor antagonists and
proton pump inhibitors [9–50].
Two CADTH assessors from two review groups (SS and FA, AL
and CY) independently applied AMSTAR to each review and
reached agreement on the assessment results. To assess construct
validity, two reviewers (JP, ZO) plus a clinician and/or
methodologist (MB, DF, DP, MO, and DH) applied a global
assessment to each review [51] (Annex S2).
Agreement and reliability
We calculated an overall agreement score using the weighted
Cohen’s kappa, as well as one for each item [52] (Table 1). Bland
and Altman’s limits of agreement methods were used to display
agreement graphically [53], [54] (Fig. 1). We calculated the
percentage of the theoretical maximum score. Pearson’s Rank
correlation coefficients were used to assess reliability of this total
score. For comparisons of rating the methodological quality we
calculated chance-corrected agreement (using kappa) and chance-
independent agreement (using W) [52], [55], [56]. We accepted a
correlation of .0.66. We further scrutinized items and reviews
with kappa scores below 0.66 [52]. Kappa values of less than 0 rate
as less than chance agreement; 0.01–0.20 slight agreement; 0.21–
0.40 fair agreement; 0.41–0.60 moderate agreement; 0.61–0.80
substantial agreement; and 0.81–0.99 almost perfect agreement
[52], [57]. We calculated PHI W for each question [55], [58].
Construct validity
We assessed construct validity (i.e. evaluation of a hypothesis about
the expected performance of an instrument) by converting the
total mean score (mean of the two assessors) for each of the 42
reviews to a percentage of the maximum score for AMSTAR and
of the maximum score of the global assessment instrument. We
used Pearson’s Rank correlation coefficients, Pearson’s R and
Kruskal-Wallis test to further explore the impact of the following
items on the construct validity of AMSTAR: a) Cochrane
systematic review vs. non-Cochrane systematic reviews [59],
[60], b) journal type [61], c) year of publication [62], d) conflict
of interest [63], e) impact factor [64], and number of pages [64].
We studied these in the context of a priori hypotheses concerning
the correlation of AMSTAR scores. Because of the nature of their
development, we anticipated that Cochrane systematic reviews
would have higher quality scores than non-Cochrane systematic
reviews and those electronic or general journals would score
higher than specialist journals. We reported on impact factors for
these journals. We hypothesized that reviews published more
recently would be of higher quality than those published earlier. In
addition, we anticipated that reviews declaring a conflict of interest
might have lower quality scores [63], [64].
We assessed the practicability of the new instrument by recording
the time it took to complete scoring and the instances where scoring
was difficult. We interviewed assessors (N = 6) to obtain data on
clarity, ambiguity, completeness and user-friendliness.
We used SPSS (versions 13 and 15) and MedCalc for Windows,
version 8.1.0.0.
RESULTS
The 42 reviews included in the study had a wide range of quality
scores. The overall scores estimated by the AMSTAR instrument
ranged from 0 to 10 (out of a maximum of 11) with a mean of 4.6
(95% CI: 3.7 to 5.6; median 4.0 (range 2.0 to 6.0). The overall
scores for the global assessment instrument ranged from 2 to 7 (out
of a maximum score of seven) with a mean of 4.43 (95% CI: 3.6 to
5.3) and median 4.0 (range 2.5 to 5.3).
Table 1. Assessment of the inter-rater agreement for AMSTAR
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Items Kappa (95% CI) PHI W
1. Was an ‘a priori’ design provided? 0.75 (0.55 to 0.96) 0.76
2. Was there duplicate study selection and data extraction? 0.81 (0.63 to 0.99) 0.83
3. Was a comprehensive literature search performed? 0.88 (0.73 to 1.00) 0.89
4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? 0.64 (0.40 to 0.88) 0.64
5. Was a list of studies (included and excluded) provided? 0.84 (0.67 to 1.00) 0.84
6. Were the characteristics of the included studies provided? 0.76 (0.55 to 0.96) 0.76
7. Was the scientific quality of the included studies assessed and documented? 0.90 (0.77 to 1.00) 0.91
8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 0.51 (0.25 to 0.78) 0.56
9. Were the methods used to combine the findings of studies appropriate? 0.80 (0.63 to 0.99) 0.80
10. Was the likelihood of publication bias assessed? 0.85 (0.64 to 1.00) 0.85
11. Were potential conflicts of interest included? 1.00 (100% no) 1.00
Overall Score 0.84 (0.67 to 1.00) 0.85
doi:10.1371/journal.pone.0001350.t001..
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Agreement and Reliability
The reliability of the total AMSTAR score between two assessors
(the sum of all items answered ‘yes’ scored as 1, all others as 0) was
(kappa 0.84 (95% CI: 0.67 to 1.00, W= 0.85) and Pearson’s R 0.96
(95% CI: 0.92 to 0.98). The inter-rater agreement (kappa) between
two raters, for the global assessment was 0.63 (95% CI: 0.40 to
0.88).
Items in AMSTAR displayed levels of agreement that ranged
from moderate to almost perfect; nine items scored a kappa of
.0.75 (0.55 to 0.96 (and W .0.76). Item 4 had a kappa of 0.64
(0.40 to 0.88) W= 0.64 and item 8 a kappa of 0.51(0.25 to 0.78
W= 0.56). The reliability of the total AMSTAR score was
excellent (kappa 0.84 (95% CI: 0.67 to 1.00 and Pearson’s R
0.96 (95% CI: 0.92 to 0.98). For the AMSTAR total score, the
limits of agreement were 20.1961.38 (Fig. 1).
The mean age of our reviewers was 40.57, median 43. Fifty-
seven percent were identified as experts in methodology and 43%
were identified as content experts in the field.
Construct validity
Expressed as a percentage of the maximum score, the results of
AMSTAR converged with the results of the global assessment
instrument [Pearson’s Rank Correlation Coefficient 0.72 (95% CI:
0.53 to 0.84)]. AMSTAR scoring also upheld our other a priori
hypotheses. The sub-analysis revealed that Cochrane reviews had
significantly higher scores than paper-based reviews with a
(R = 37.21 n = 7) for Cochrane reviews and (R = 18.36 n = 35)
for paper-based (P,0.0002). Cochrane reviews (R = 37.21 n = 7)
also scored higher than reviews published in general journals
(R = 25.77 n = 11) and specialty journals (R = 14.96, n = 24)
(P,0.0001). Reviews published from 2000 onward had higher
AMSTAR scores than earlier reviews (R = 25.20, n = 25 vs.
R = 13.12, n = 17; P = 0.0002).
The journals had the following overall summary statistics for the
impact factors: mean 5.88 (95% CI: 3.9 to 7.9) median 3.3 (lowest
value 1.4, highest value 23.9). There is no statistical association
between AMSTAR score and impact factor (Pearson’s R (0.555
P = 0.7922)). There was however a significant association found
with the number of pages and AMSTAR scores (Pearson’s R
(0.5623 P = 0.0001 n = 42). We found no association (R 0.1773
P = 0.0308) when we removed the outliers (i.e. systematic reviews
with higher page numbers).
Conflict of interest was poorly presented. Of the 42 reviews
assessed, no study had appropriately declared their conflict of
interest. Therefore, we were unable to assess whether or not
funding had a positive or negative effect on the AMSTAR score.
Practicability
Both AMSTAR and the global assessment required on average
15 minutes to complete, but with the latter, assessors expressed
difficulty in reaching a final decision in the absence of comprehensive
guidelines. In contrast, AMSTAR was well received.
DISCUSSION
Principal findings
This paper describes an external validation of AMSTAR. This
new measurement tool to assess methodological quality of
systematic reviews showed satisfactory inter-observer agreement,
reliability and construct validity in this study. Items in AMSTAR
displayed levels of agreement that ranged from moderate to almost
perfect. The reliability of the total AMSTAR score was excellent.
Construct validity was shown by AMSTAR convergence with the
results of the global assessment instrument.
We found a significant association between number of published
pages and overall AMSTAR score, suggesting that the longer the
manuscript, the higher the quality score. It should be interpreted
with caution given the fact that only a couple of the longer reviews
largely drive the hypothesis tests. We found no association when
the outliers were removed from the dataset. We did not find an
association between AMSTAR score and impact factor.
The AMSTAR instrument was developed pragmatically using
previously published tools and expert consensus. The original 37
items were reduced to an 11- item instrument addressing key
domains; the resulting instrument was judged by the expert panel
to have face and content validity [7].
Strengths and weaknesses of the study
This is a prospective external validation study. We compared the
new instrument to an independent and reliable gold standard
designed for assessing the quality of systematic reviews, allowing
multiple testing of convergent validity.
The analytical methods for assessing quality and measuring
agreement amongst assessors need further discussion and devel-
opment. We calculated chance-corrected agreement, using the
kappa statistic [57], [65]. While avoiding high levels of agreement
due to chance, kappa has its own limitations that have lead to
academic criticism [66], [67]. One of the major difficulties with
kappa is that when the proportion of positive ratings is extreme,
the possible agreement above chance agreement is small and it is
difficult to achieve even moderate values of kappa. Thus, if one
uses the same raters in a variety of settings, as the proportion of
positive ratings becomes extreme, kappa will decrease even if the
manner in which the assessors rate the quality does not change. To
address this limitation, we also calculated chance-independent
agreement using PHIW, a relatively new approach to assessing
observer agreement [55], [58].
We were unable to test our convergent validity hypothesis about
conflict of interest because of missing data in the systematic
reviews and primary studies. This highlights the need for journals
and journal editors to require that the information is provided.
Our results are based on a small sample of systematic reviews in
a particular clinical area and a relatively small number of
AMSTAR assessors. There is a need for replication in larger
and different data sets with more diverse appraisers.
Figure 1. Bland and Altman limits of agreement plot for AMSTAR
scores.
doi:10.1371/journal.pone.0001350.g001
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Possible mechanisms and implications for clinicians
or policymakers
Existing systematic review appraisal instrument did not reflect
current evidence on potential sources of bias in systematic reviews
and were generally not validated. The best available instrument
prior to the development of AMSTAR was OQAQ which was
formally validated. However, users of OQAQ frequently had to
develop their own rules for operationalizing the instrument and
OQAQ does not reflect current evidence on sources of potential
bias in systematic reviews (for example funding source and conflict
of interest [68,69,70]).
Quality assessment instruments can focus on either reporting
quality (how well systematic reviewers have reported their
methodology and findings (internal validity) or methodological quality
(how well the systematic review was conducted (literature
searching, pooling of data, etc.). It is possible for a systematic
review with poor methodological quality to have good reporting
quality. For this reason, the AMSTAR items focus on method-
ological quality.
Decision-makers have spent the last ten years trying to work out
the best way to use the enormous amounts of systematic reviews
available to them. They can hardly know where to start when
deciding whether the relevant literature is valid and of the highest
quality. AMSTAR is a user friendly methodological quality
assessment that has the potential to standardize appraisal of
systematic reviews. Early experience suggests that relevant groups
are finding the instrument useful.
Unanswered questions and future research
Further validation of AMSTAR is needed to assess its validity,
reliability and perceived utility by appraisers and end users of
reviews across a broader range of systematic reviews. We need to
assess the responsiveness of AMSTAR looking at its sensitivity to
discriminate between high and low methodological quality
reviews.
We need to assess the applicability of AMSTAR for reviews of
observational (diagnostic, etiological and prognostic) studies and if
necessary develop AMSTAR extensions for these reviews.
We plan to update AMSTAR as new evidence regarding
sources of bias within systematic reviews becomes available.
SUPPORTING INFORMATION
Annex S1 AMSTAR is a measurement tool created to assess the
methodological quality of systematic reviews.
Found at: doi:10.1371/journal.pone.0001350.s001 (0.04 MB
DOC)
Annex S2 Global assessment rating
Found at: doi:10.1371/journal.pone.0001350.s002 (0.03 MB
DOC)
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